Personal information

HBcrAg, HCC, IBD, PIVKA-II
Italy

Activities

Employment (1)

Università degli Studi di Torino: Turin, IT

2021-12-28 to present | Assistant Professor (Medical Sciences)
Employment
Source: Self-asserted source
Gian Paolo Caviglia

Education and qualifications (4)

University of Pavia: Pavia, IT

2010-11-02 to present | Licensed to Biology practice
Qualification
Source: Self-asserted source
Gian Paolo Caviglia

University of Turin: Turin, IT

2012-01-01 to 2015-12-31 | PhD (Medical Sciences)
Education
Source: Self-asserted source
Gian Paolo Caviglia

University of Turin: Turin, IT

2006-11-24 to 2009-04-22 | MSc
Education
Source: Self-asserted source
Gian Paolo Caviglia

University of Turin: Turin, IT

2001-09-20 to 2006-03-20 | BSc
Education
Source: Self-asserted source
Gian Paolo Caviglia

Professional activities (8)

Associazione Italiana per lo Studio del Fegato: Rome, IT

Membership
Source: Self-asserted source
Gian Paolo Caviglia

Frontiers Media SA: Lausanne, VD, CH

2023 to present
Service
Source: Self-asserted source
Gian Paolo Caviglia

Diagnostics: Basel, CH

2022 to present | Editorial Board Member
Service
Source: Self-asserted source
Gian Paolo Caviglia

World Journal of Hepatology: Pleasanton, US

2021 to present | Editorial Board Member
Service
Source: Self-asserted source
Gian Paolo Caviglia

Journal of Clinical Medicine: Basel, CH

2021 to present | Editorial Board Member
Service
Source: Self-asserted source
Gian Paolo Caviglia

Current Oncology: Basel, BS, CH

2021 to present | Editorial Board Member (Current Oncology)
Service
Source: Self-asserted source
Gian Paolo Caviglia

Viruses: Basel, CH

2020 to present | Reviewer Board Member
Service
Source: Self-asserted source
Gian Paolo Caviglia

Minerva Biotechnology and Biomolecular Research: Turin, IT

2020 to present | Editorial Board Member
Service
Source: Self-asserted source
Gian Paolo Caviglia

Funding (3)

A case-control study to investigate the ability of serum Glypican-3 to discriminate between patients with HCC and benign liver disease induced by dysmetabolic liver disease (NAFLD)

2021 to 2021 | Contract
Fujirebio Diagnostics AB (Gothenburg, SE)
Source: Self-asserted source
Gian Paolo Caviglia

Clinical role of Glypican 3 as a seum-based marker for early detection of HCC

2019-12 to 2021-01 | Contract
Fujirebio Diagnostics AB (Gothenburg, SE)
Source: Self-asserted source
Gian Paolo Caviglia

Novel quantitative serological assays (HBcrAg and anti-HBc IgG) in the management of chronic hepatitis B infection

2018-10 to 2019-09 | Contract
Fujirebio Europe (Gent, BE)
GRANT_NUMBER:

CMD REF 01-10-02517

Source: Self-asserted source
Gian Paolo Caviglia

Peer review (266 reviews for 60 publications/grants)

Review activity for Alimentary pharmacology & therapeutics. (4)
Review activity for Annals of hepatology. (1)
Review activity for Annals of medicine (2)
Review activity for Arab Journal of Gastroenterology (1)
Review activity for Biochimica et biophysica acta CR. (1)
Review activity for Biology. (2)
Review activity for BioMed research international. (2)
Review activity for Biomedicines. (6)
Review activity for Biomolecules. (2)
Review activity for BMC gastroenterology (2)
Review activity for Cancer medicine. (1)
Review activity for Cancers. (40)
Review activity for Clinical and translational gastroenterology. (1)
Review activity for Clinical microbiology and infection (1)
Review activity for Current oncology. (2)
Review activity for Diagnostics. (13)
Review activity for Disease markers (1)
Review activity for Disease markers. (3)
Review activity for Drugs & therapy perspectives (3)
Review activity for Expert review of anticancer therapy (1)
Review activity for Expert review of gastroenterology & hepatology. (2)
Review activity for Future oncology. (2)
Review activity for Future virology. (2)
Review activity for Gastrointestinal disorders. (4)
Review activity for Gut (1)
Review activity for Hepatobiliary & pancreatic diseases international. (2)
Review activity for International journal of experimental pathology. (1)
Review activity for International journal of infectious diseases. (2)
Review activity for International journal of molecular sciences. (5)
Review activity for International journal of molecular sciences. (3)
Review activity for Journal of clinical and translational hepatology. (3)
Review activity for Journal of clinical laboratory analysis. (11)
Review activity for Journal of clinical medicine. (55)
Review activity for Journal of dermatological treatment. (1)
Review activity for Journal of medical virology. (3)
Review activity for Journal of personalized medicine. (2)
Review activity for Journal of viral hepatitis. (2)
Review activity for Laboratory medicine. (3)
Review activity for Leukemia and lymphoma. (1)
Review activity for Life. (2)
Review activity for Liver international. (1)
Review activity for Marine drugs. (2)
Review activity for Medicina. (3)
Review activity for Methods. (1)
Review activity for Microorganisms. (7)
Review activity for Minerva biotecnologica. (1)
Review activity for Minerva gastroenterologica e dietologica. (1)
Review activity for Minerva gastroenterology (3)
Review activity for Minerva medica. (2)
Review activity for Molecules. (2)
Review activity for Nutrients. (3)
Review activity for Pathogens. (5)
Review activity for Pharmaceuticals. (1)
Review activity for Practical laboratory medicine. (1)
Review activity for Technology in cancer research & treatment. (3)
Review activity for Translational cancer research. (1)
Review activity for Vaccines. (2)
Review activity for Viruses. (22)
Review activity for World journal of gastroenterology. (8)
Review activity for World journal of hepatology. (1)